We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+32.17%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.01B
AUM Growth
+$300M
Cap. Flow
-$394M
Cap. Flow %
-7.86%
Top 10 Hldgs %
36.48%
Holding
142
New
15
Increased
17
Reduced
27
Closed
32

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$105M
2
BIIB icon
Biogen
BIIB
+$66.5M
3
ELV icon
Elevance Health
ELV
+$65.4M
4
SRRK icon
Scholar Rock
SRRK
+$27.5M
5
ARGX icon
argenx
ARGX
+$24.2M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$115M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
3
BAX icon
Baxter International
BAX
+$84.5M
4
CI icon
Cigna
CI
+$66.2M
5
ABBV icon
AbbVie
ABBV
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Industrials 1.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
76
Heron Therapeutics
HRTX
$93.1M
$10.1M 0.2%
5,928,591
+5,125,891
+639% +$5.64M
ARWR icon
77
Arrowhead Research
ARWR
$12.2B
$9.78M 0.2%
319,651
-114,000
-26% -$3.03M
QURE icon
78
uniQure
QURE
$2.72B
$9.13M 0.18%
1,347,900
-716,555
-35% -$4.74M
DXCM icon
79
DexCom
DXCM
$29B
$9.08M 0.18%
+73,200
New +$7.48M
APLM icon
80
Apollomics
APLM
$40M
$8.27M 0.17%
85,655
-94,281
-52% -$11.6M
GILD icon
81
Gilead Sciences
GILD
$166B
$8.1M 0.16%
100,000
– –
MORF
82
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.9M 0.16%
273,400
+64,900
+31% +$1.55M
TSBX
83
DELISTED
Turnstone Biologics
TSBX
$7.89M 0.16%
3,099,265
– –
RAPT
84
DELISTED
RAPT Therapeutics
RAPT
$6.99M 0.14%
35,177
-120,441
-77% -$14.9M
IMA
85
ImageneBio Inc
IMA
$64.2M
$6.97M 0.14%
294,947
+29,433
+11% +$960K
NSPR icon
86
InspireMD
NSPR
$30.9M
$5.99M 0.12%
2,133,405
+273,000
+15% +$786K
XFOR icon
87
X4 Pharmaceuticals
XFOR
$376M
$5.98M 0.12%
237,784
– –
CGEM icon
88
Cullinan Oncology
CGEM
$1.07B
$5.55M 0.11%
544,848
– –
ORIC icon
89
Oric Pharmaceuticals
ORIC
$1.2B
$4.81M 0.1%
522,968
-370,700
-41% -$2.68M
ILMN icon
90
Illumina
ILMN
$29.4B
$4.22M 0.08%
+31,148
New +$3.59M
AMAM
91
DELISTED
Ambrx Biopharma Inc
AMAM
$4.22M 0.08%
+296,000
New +$3.36M
NXTC icon
92
NextCure
NXTC
$21.2M
$3.09M 0.06%
225,918
– –
CLDX icon
93
Celldex Therapeutics
CLDX
$2.82B
$2.33M 0.05%
+58,800
New +$1.73M
RCUS icon
94
Arcus Biosciences
RCUS
$3.37B
$2.23M 0.04%
+117,000
New +$1.87M
TXG icon
95
10x Genomics
TXG
$5.96B
$2.23M 0.04%
+39,800
New +$1.73M
FATE icon
96
Fate Therapeutics
FATE
$267M
$1.98M 0.04%
+528,080
New +$1.25M
KZR
97
DELISTED
Kezar Life Sciences
KZR
$1.83M 0.04%
192,700
-353,600
-65% -$3.11M
BOLT icon
98
Bolt Biotherapeutics
BOLT
$7.72M
$1.73M 0.03%
77,050
– –
LSB
99
DELISTED
LakeShore Biopharma
LSB
$1.65M 0.03%
323,631
-130,511
-29% -$751K
VIGL
100
DELISTED
Vigil Neuroscience
VIGL
$1.52M 0.03%
448,891
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2023 Portfolio in Review

As of Q4 2023, OrbiMed held 142 positions worth $5.01B, up 6.4% from $4.71B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed withdrew a net $394M in Q4 2023, closing 32 positions and reducing 27 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, OrbiMed opened a new position in Elevance Health worth $66.7M.

  • OrbiMed's largest Q4 2023 buy was Elevance Health: 141,500 shares worth $66.7M.
  • OrbiMed added most to Eli Lilly in Q4 2023, an estimated $105M increase.
  • OrbiMed's biggest Q4 2023 reduction was Humana, cutting an estimated $115M.
  • OrbiMed fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $85.3M.
  • OrbiMed's ten largest holdings make up 36% of its $5.01B portfolio in Q4 2023.
  • OrbiMed opened 15 new positions and closed 32 in Q4 2023.
  • OrbiMed's portfolio value rose 6.4% quarter-over-quarter to $5.01B.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.